Advanced Biomed Inc（ADVB）股票分析ADVBAdvanced Biomed Inc

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip. It operates in the Healthcare sector.

Given the current price of $3.17 and an RSI of 8.77, which indicates extreme oversold conditions, it may seem tempting to buy. However, the stock has a troubling 5-day change of -20.35% and a 1-year change of -64.79%, suggesting a significant downtrend. The forward P/E ratio is 0, indicating uncertainty about future earnings, and the company has reported negative net income in multiple recent quarters, including a loss of $488,942 in Q3 2026. Therefore, the risks outweigh the potential upside, and it is advisable to sell or avoid buying ADVB at this time.